Ferma Blog

ESMO Congress 2026: What 20 Oncologists Took Home | Ferma

Written by Aravindha Kumar | Nov 18, 2026, 2:05:13 PM

ESMO Congress 2026 ran in Madrid from 23 to 27 October. In the two weeks that followed, we interviewed 20 practising oncologists in Italy, Germany, Spain, the UK, France and the US about the data they saw. They agreed on one practice-changing study, raised one we had not asked about, and differed most on how fast the data will reach patients. 

Which ESMO 2026 study do oncologists expect to change practice?

DeLLphi-305. All 11 oncologists who discussed it in depth called it practice-changing, and 8 of the 9 who compared it with IMforte (atezolizumab plus lurbinectedin) would use it instead. Asked what they would tell a colleague about, 7 of 20 named DeLLphi-305. The next most-named study, INTerpath-001, was named by 4. 

The trial, presented in the Presidential Symposium, tested tarlatamab plus durvalumab as first-line maintenance in extensive-stage small cell lung cancer. Median overall survival was 21.1 months, against 12.7 months with durvalumab alone (hazard ratio, HR, 0.42). Median progression-free survival was 7.4 vs 1.9 months. 

The new regimen is unlikely to put many more patients on maintenance. 8 of 11 said that share stays the same, because response to the first treatment decides it. The catch is giving it: patients need closer watching at the start. Oncologists in the US, Italy, the UK and France raised hospital or day-hospital starts, monitoring plans and scaling up. Cytokine release syndrome (CRS) affected about half of patients on the combination (49.6%), almost all mild (grade 1 or 2). 

“I think it is definitely practice-changing to use tarlatamab with durvalumab in the maintenance setting.”
Haematologist-oncologist, community hospital, US

“Immediately, since both treatments are already available.”
Medical oncologist, community hospital, France, on when DeLLphi-305 will change practice

Can a second ADC work after the first?

Most oncologists think so, but most also want a different treatment in between. We asked all 20 to rate four statements about giving one antibody-drug conjugate (ADC) after another: 

  • 18 of 20 agree a second ADC can work if it carries a different payload
  • 16 of 20 agree it can work if it targets a different antigen
  • 17 of 20 agree that, ideally, both should differ
  • 13 of 20 agree the patient should first receive a different type of treatment, such as chemotherapy; 5 disagree

The question matters more after ESMO 2026 brought positive Phase 3 ADC results in new tumour types. In TroFuse-005, sacituzumab tirumotecan, a TROP2-directed ADC, extended median overall survival to 19.0 months, against 12.1 months with physician's choice of chemotherapy, in previously treated endometrial cancer (HR 0.68). In CLARITY-Gastric01, sonesitatug vedotin, a claudin 18.2-directed ADC, doubled median overall survival to 10.0 months from 5.0 months in third-line or later gastric and gastroesophageal cancer (HR 0.47). 

Where these drugs fit is still open. A French oncologist would make sacituzumab tirumotecan the second-line standard in endometrial cancer after immunochemotherapy; a UK oncologist would hold it for third line. For claudin 18.2 gastric cancer, two German oncologists would use sonesitatug vedotin in second line and a US oncologist in third line, while an Italian oncologist would test every patient for claudin 18.2. 

“I would probably leave it to third line and use other biomarker-targeted therapy in second line.”
Consultant oncologist, NHS, UK, on TroFuse-005

How will the SAFFRON trial change MET testing after osimertinib?

Most oncologists would now test every patient for MET when the disease progresses on osimertinib: 8 of the 10 we asked. What slows it down is getting a new biopsy and lab capacity. One Spanish oncologist estimated about half of patients, and another noted that testing is not yet routine. 

SAFFRON compared osimertinib plus savolitinib with platinum-pemetrexed chemotherapy in 338 patients with EGFR-mutated non-small cell lung cancer and MET overexpression or amplification after osimertinib. Median progression-free survival was 7.6 vs 5.4 months (HR 0.55), and median overall survival 17.8 vs 12.9 months (HR 0.68). 

“The results of SAFFRON are good news for patients, but they are a challenge for clinicians, who will need to be more insistent about re-biopsying patients at progression.”
Thoracic oncologist, academic hospital, France

Which study did oncologists raise without being asked?

KRAS G12C lung cancer. It was not on the list of studies we asked about, yet 7 of 20 oncologists brought it up on their own. The data behind it is Krascendo 1, a Phase 3 late-breaker (LBA5) at ESMO 2026. 

Krascendo 1 compared divarasib with sotorasib or adagrasib in 338 patients with previously treated KRAS G12C non-small cell lung cancer (NSCLC). Median progression-free survival was 9.8 months with divarasib, against 5.7 months with the first-generation KRAS G12C inhibitors (HR 0.58). At the first interim analysis, median overall survival was 17.7 vs 12.0 months (HR 0.56). 

How fast will ESMO 2026 data reach patients?

It ranges from immediately to two years or more. What slows it down is each country's approval and payment process, not doubt about the data. The table shows what oncologists in each country told us; the number of doctors behind each view is small. 

Country (oncologists) Expected time to practice What sets the pace
France (3) Immediate where the drug already has a label; 3 months to a year for new drugs  Payment approval for a new line; early access for new drugs 
Germany (4) Immediately to a few months after approval  Practical steps: MET testing, checks for lung side effects, CRS monitoring 
US (2) A few months after approval; one oncologist expects about three months  Access and monitoring burden 
Spain (3) 6 to 12 months Marketed drugs move faster; SAFFRON waits for its indication and routine MET testing 
Italy (5) 1 to 2 years Slow approvals; compassionate use is the only early route; the gap between large and smaller centres is widening 
UK (3) 1 to 2 years Funding and new care pathways; one oncologist sees no SAFFRON-driven change for five years 

“At least a year to a year and a half, because appropriate upfront testing must be ensured for all patients.”
Thoracic medical oncologist, academic centre, Italy, on SAFFRON

What does this mean for your team?

If you have a drug launching in small cell lung cancer, plan for monitoring support, not just awareness. If you work in EGFR lung cancer, access to testing will decide uptake more than the data. And if you are planning launches across Europe, expect the same data to reach patients a year or more apart. 

How was this research done?

We ran 20 AI-moderated voice interviews, most lasting about 10 to 15 minutes, in the two weeks after the congress, with oncologists from ZoomRx's HCP panel: Italy 5, Germany 4, Spain 3, UK 3, France 3, US 2. Interviews combined open questions, detailed questions on selected studies and four statements about giving one ADC after another. 

These are qualitative findings from a small sample. Numbers are counts of doctors, not shares of the market. Trial results in this article are as presented at ESMO 2026, not doctors' recall. 

We ran these interviews as HCP Conversations, one of the datasets in Ferma. In Ferma, what doctors said sits next to what was presented at the congress and the trial and pipeline data behind it, so your team can ask one question and see both. 

Read the full ESMO 2026 readout →

 

 

Frequently asked questions